HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A significant shift in the shareholding pattern of pharmaceutical player Corona Remedies Limited took place on June 17, 2026, as major institutional investors moved to acquire substantial stakes. The massive block deal saw marquee names like HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA) entering the fray, signaling strong institutional confidence in the company.
Massive Divestment by Sepia Investments and Anchor Partners
The block deal was primarily driven by the exit of two major sellers. Sepia Investments offloaded 43,28,943 shares of Corona Remedies at a price of ₹1,730 per share, amounting to a deal value of approximately ₹748.9 crore. Adding to this volume, Anchor Partners divested 1,61,861 shares at the same price, contributing another ₹28 crore to the transaction. Combined, these two entities offloaded shares worth roughly ₹776.9 crore in the pharmaceutical company.
HDFC Mutual Fund Dominates the Buy Side
The absorption of these shares was led by a diverse group of twelve institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, acquiring 24,50,000 shares worth approximately ₹423.9 crore. This single transaction accounted for more than half of the total deal value, underscoring HDFC MF's significant conviction in the stock's future prospects.
Other prominent domestic and international players also participated heavily:
- Aditya Birla Sun Life Mutual Fund acquired 4,90,000 shares worth ₹84.8 crore.
- Invesco Mutual Fund picked up 2,89,017 shares, valued at around ₹50 crore.
- Kotak Mahindra Mutual Fund bought 1,61,861 shares, matching the exact quantity sold by Anchor Partners, worth ₹28 crore.
Global Institutional Interest in Corona Remedies
The deal also highlighted significant interest from global fund managers and sovereign wealth funds. Aberdeen Asian Smaller Companies Investment Trust Plc purchased 4,50,868 shares for approximately ₹78 crore, while the Aberdeen Standard Sicav I - Asian Smaller Companies Fund took up 2,74,132 shares worth ₹47.4 crore.
Furthermore, the Abu Dhabi Investment Authority (ADIA) entered the cap table by purchasing 39,130 shares worth ₹6.8 crore. Other international participants included WhiteOak Capital Mutual Fund, which invested ₹25.1 crore, and the India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund, which bought shares worth ₹25.7 crore. Even smaller niche players like Factory Mutual Insurance Company participated, picking up 10,670 shares worth ₹1.9 crore.
Key Takeaways
- Major Institutional Exit: Sepia Investments and Anchor Partners exited a combined position worth approximately ₹776.9 crore in Corona Remedies.
- HDFC MF Leads Buying: HDFC Mutual Fund was the primary acquirer, snapping up ₹423.9 crore worth of shares, representing over 50% of the total deal value.
- High Institutional Confidence: The participation of global entities like ADIA and various Aberdeen funds suggests strong cross-border institutional interest in the pharma sector.